Citi analyst Yigal Nochomovitz has maintained their bullish stance on ARCT stock, giving a Buy rating on July 11.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Yigal Nochomovitz has given his Buy rating due to a combination of factors surrounding Arcturus Therapeutics’ promising developments in their mRNA therapies. The company is positioned to potentially lead the market with its ARCT-032 therapy for cystic fibrosis (CF), as it is ahead of its competitors in clinical trials. With key interim data expected mid-year, the risk/reward profile appears favorable, especially given the low threshold for success in improving lung function in CF patients.
Furthermore, Arcturus Therapeutics’ recent positive updates on their OTC program and the anticipated progress in their Phase 1b trials provide additional confidence in the company’s growth potential. The expected share price return of 246.6% underscores the high potential upside, making it an attractive investment opportunity despite the associated risks.
In another report released on July 11, Piper Sandler also maintained a Buy rating on the stock with a $140.00 price target.
ARCT’s price has also changed moderately for the past six months – from $16.590 to $13.310, which is a -19.77% drop .